In the build-up to the second annual AI in Pharma Summit 2018 (Oct 9th, Boston, MA), I caught up with Kim Branson from Genentech to hear his insights on the crucial barriers and opportunities facing the application of AI in Pharma.
As a true AI champion and with having worked with AI for over 15 years, both outside and inside of pharma, Kim provides a unique take on how pharma should look to extract maximum value from AI.
Kim has been involved in large-scale machine learning and medical informatics initiatives for over 15 years, over a range of ventures from computational drug design to disease risk prediction. He is currently the head of Artificial Intelligence for the Informatics department of Early Clinical Development at Genentech. Recently, he served as Chief Data Scientist at Lumiata, a predictive health analytics company. Kim received degrees from the University of Adelaide, and a PhD from the University of Melbourne (Australia). He was a Peter Doherty fellow and received postdoctoral training at the University of Cambridge and Stanford University. He then held leadership and consulting roles in the pharmaceutical and medical informatics industry, notably at Vertex. Following this, Kim worked extensively in online search at Discovery Engine (acquired by Twitter in 2009) and health informatics at Gliimpse (acquired by Apple in 2017).